Detalles de la búsqueda
1.
Plasma neutralization properties of the SARS-CoV-2 Omicron variant
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21267646
2.
Persistent Cellular Immunity to SARS-CoV-2 Infection
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-416636
3.
TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21251089
4.
SARS-CoV-2 neutralization after mRNA vaccination and variant breakthrough infection
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22270692
5.
High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-455491
6.
Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-504313
7.
Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22278483
8.
Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-480394
9.
Antibody Evolution after SARS-CoV-2 mRNA Vaccination
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-454333
10.
Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-435863
11.
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-434227
12.
SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-431043
13.
Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-503601
14.
Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-288555
15.
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-214759
16.
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-140871
17.
Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-121533
18.
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-486548
19.
Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-478695
20.
Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-443175